Novel monoclonal antibody therapy for SARS-CoV-2 northwesternu jclinicalinvest
The SARS-CoV-2 spike protein is the main antigen in all approved COVID-19 vaccines and is also the only target for monoclonal antibody therapies. Immune responses to other viral antigens are generated after SARS-CoV-2 infection, but their contribution to the antiviral response remains unclear. Here, we interrogate whether nucleocapsid-specific antibodies can improve protection against SARSCoV-2.
We show that mice that received nucleocapsid-specific sera or a nucleocapsid-specific monoclonal antibody exhibited enhanced control of SARS-CoV-2. Nucleocapsid-specific antibodies elicited NK-mediated antibodydependent cellular cytotoxicity against infected cells.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: